SCHEMBL343766

SCHEMBL343766

CCC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.58

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.58
LMNA P02545 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.50
TDP1 Q9NUW8 1/20 0.48
USP2 O75604 1/20 0.43
SLCO1B1 Q9Y6L6 1/20 0.43
KDM4E B2RXH2 2/20 0.41
CYP2C9 P11712 1/20 0.37
TSHR P16473 1/20 0.37
TOP1 P11387 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13998446 1.00 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL13998326 1.00 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL8083544 1.00 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL29756403 1.00 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL9965102 1.00 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL8095380 1.00 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL4160010 1.00 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
Ammonia Solution, Strong SCHEMBL28915080 0.98 PDE4A (0.56) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL15239580 0.93 PDE4A (0.48) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL13879019 0.93 PDE4A (0.48) PDE4ALMNAL3MBTL1TDP1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114456791-B Deep water oil-gas field liquid foam discharging agent and production process thereof 中海油(天津)油田化工有限公司 2023-06-02 CN claimed
CN-109001337-B Method for detecting polysaccharide content of mesona blume 广州中医药大学(广州中医药研究院) 2021-05-18 CN claimed
EP-3740212-A2 CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY Merck Sharp & Dohme Corp. (US) 2020-11-25 EP claimed
CN-109001337-A A kind of detection method of Chinese mesona herb polyoses content 广州中医药大学(广州中医药研究院) 2018-12-14 CN claimed
CN-107213025-A A kind of microcapsules lotion and preparation method thereof 江振杰 2017-09-29 CN claimed
US-9114176-B2 Exogenously triggered controlled release materials and uses thereof SMARTCELLS, INC. (US) 2015-08-25 US claimed
US-8940690-B2 Synthetic conjugates and uses thereof NATIONAL INSTITUTES OF HEALTH (NIH) (US) 2015-01-27 US claimed
US-20140342980-A1 BINDING-SITE MODIFIED LECTINS AND USES THEREOF SMARTCELLS INC (US) 2014-11-20 US claimed
US-8846103-B2 Exogenously triggered controlled release materials and uses thereof SMARTCELLS, INC. (US) 2014-09-30 US claimed
US-20140256622-A1 EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF SMARTCELLS, INC. (US) 2014-09-11 US claimed
US-20110281792-A1 BINDING-SITE MODIFIED LECTINS AND USES THEREOF SMARTCELLS, INC. 2011-11-17 US claimed
US-20110275560-A1 SYNTHETIC CONJUGATES AND USES THEREOF SMARTCELLS, INC. 2011-11-10 US claimed
WO-2010107520-A1 SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF SMARTCELLS, INC. (US) 2010-09-23 WO claimed
WO-2010107519-A1 TERMINALLY-FUNCTIONALIZED CONJUGATES AND USES THEREOF SMARTCELLS, INC. (US) 2010-09-23 WO claimed
WO-2010088286-A1 SYNTHETIC CONJUGATES AND USES THEREOF SMARTCELLS, INC. (US) 2010-08-05 WO claimed
WO-2010088276-A2 POLYNUCLEOTIDE APTAMER-BASED CROSS -LINKED MATERIALS AND USES THEREOF SMARTCELLS, INC. (US) 2010-08-05 WO claimed
WO-2010088261-A1 BINDING-SITE MODIFIED LECTINS AND USES THEREOF SMARTCELLS, INC. (US) 2010-08-05 WO claimed
WO-2010088268-A1 EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF SMARTCELLS, INC. (US) 2010-08-05 WO claimed
WO-2010088294-A1 CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY SMARTCELLS, INC. (US) 2010-08-05 WO claimed
EP-0576691-B1 Detergent composition LION CORP (JP) 1998-01-21 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275560-A1 SYNTHETIC CONJUGATES AND USES THEREOF SLC2A4, SLC2A8, CD44 PDE4A 4326/4885LMNA 4457/4885L3MBTL1 1047/4885
US-20140342980-A1 BINDING-SITE MODIFIED LECTINS AND USES THEREOF SIGLEC7, SIGLEC9, LGALS3BP PDE4A 3569/4885LMNA 1669/4885L3MBTL1 295/4885
US-20110281792-A1 BINDING-SITE MODIFIED LECTINS AND USES THEREOF SIGLEC7, SIGLEC9, LGALS3BP PDE4A 3569/4885LMNA 1669/4885L3MBTL1 295/4885
US-20140256622-A1 EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF CD63, EPHA2, CNDP2 PDE4A 2557/4885LMNA 2715/4885L3MBTL1 3117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.